All In Biotech

Drug Trial Radar · NCT01339559

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

767

Actual

Start

May 11, 2011

Primary completion

Apr 18, 2019

Study completion Apr 18, 2019

Sponsor

Lead sponsor
UCB BIOSCIENCES, Inc.UCB
Sponsor type
Industry
First posted
Apr 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).

Conditions

  • Epilepsy

Interventions

  • BrivaracetamDrug

    Tablet, Flexible dosing up to 200 mg/day, twice daily. The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
  2. Percentage of Participants Who Withdrew Due to Adverse Events (AEs)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
  3. Percentage of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)

Locations

184 sites in 28 countries. Site status is shown where the registry gives one.

  • 001

    Phoenix, Arizona

  • 013

    Phoenix, Arizona

  • 006

    Tucson, Arizona

  • 775

    Little Rock, Arkansas

  • 025

    San Francisco, California

  • 060

    Aurora, Colorado

  • 071

    Miami, Florida

  • 027

    Orlando, Florida

  • 064

    Port Charlotte, Florida

  • 023

    Atlanta, Georgia

  • 048

    Rome, Georgia

  • 039

    Boise, Idaho

  • 029

    Chicago, Illinois

  • 005

    Peoria, Illinois

  • 017

    Winfield, Illinois

  • 020

    Ames, Iowa

  • 069

    Iowa City, Iowa

  • 780

    Lexington, Kentucky

  • 008

    Bethesda, Maryland

  • 068

    Waldorf, Maryland

  • 009

    Golden Valley, Minnesota

  • 032

    Lebanon, New Hampshire

  • 042

    Hamilton, New Jersey

  • 099

    New York, New York

  • 022

    New York, New York

  • 098

    Poughkeepsie, New York

  • 010

    Asheville, North Carolina

  • 003

    Durham, North Carolina

  • 034

    Cleveland, Ohio

  • 778

    Columbus, Ohio

  • 070

    Columbus, Ohio

  • 002

    Toledo, Ohio

  • 043

    Oklahoma City, Oklahoma

  • 091

    Oklahoma City, Oklahoma

  • 054

    Tulsa, Oklahoma

  • 015

    Philadelphia, Pennsylvania

  • 028

    Charleston, South Carolina

  • 021

    Port Royal, South Carolina

  • 776

    Nashville, Tennessee

  • 061

    Austin, Texas

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.